Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received an average rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $5.67.

Several research analysts recently weighed in on SGMO shares. Royal Bank of Canada restated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a research note on Wednesday, May 15th. Finally, StockNews.com started coverage on shares of Sangamo Therapeutics in a research note on Friday. They issued a “sell” rating for the company.

Sangamo Therapeutics Trading Up 9.9 %

Shares of SGMO stock opened at $0.44 on Friday. The business’s fifty day simple moving average is $0.50 and its 200-day simple moving average is $0.61. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.67. The company has a market cap of $90.97 million, a PE ratio of -0.24 and a beta of 1.24.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $8.51 million. Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. During the same quarter in the prior year, the firm earned $0.12 earnings per share. On average, equities analysts forecast that Sangamo Therapeutics will post -0.55 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC boosted its holdings in shares of Sangamo Therapeutics by 4.0% in the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after acquiring an additional 192,385 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 23,650 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Sangamo Therapeutics in the 1st quarter valued at about $331,000. Wasatch Advisors LP increased its stake in Sangamo Therapeutics by 62.4% in the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after buying an additional 7,734,400 shares during the period. Finally, Golden State Equity Partners lifted its position in Sangamo Therapeutics by 21.0% in the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 34,960 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.